pituitary adenoma/prolactin secreting (prolactinoma)

From Aaushi
Jump to navigation Jump to search

Epidemiology

Pathology

  • women
    • almost always small tumors (microadenomas)
    • clinical course is benign
    • tumors rarely enlarge
  • men
    • generally large tumors (macroadenomas)
    • often aggressive tumors

Genetics

  • associated with defects in AIP

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

* dopaminergic agonists decrease size of prolactinomas > 50% in 80-90% of patients[1]

More general terms

Additional terms

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018.
  2. Klibanski A Clinical practice. Prolactinomas. N Engl J Med. 2010 Apr 1;362(13):1219-26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20357284
  3. Mann WA Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest. 2011 Mar;41(3):334-42.
  4. 4.0 4.1 NEJM Knowledge+
  5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) web page "Prolactinoma" http://www.niddk.nih.gov/health/endo/pubs/prolact/prolact.htm

Database